CWM
SUPN icon

Catamount Wealth Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Catamount Wealth Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$5K Hold
150
– – ﹤0.01% 159
2018
Q4 		$6K Hold
150
– – ﹤0.01% 152
2018
Q3 		$8K Hold
150
– – ﹤0.01% 152
2018
Q2 		$7K Hold
150
– – ﹤0.01% 153
2018
Q1 		$7K Hold
150
– – ﹤0.01% 143
2017
Q4 		$6K Buy
+150
New +$5.93K ﹤0.01% 152

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
NPIC
Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Catamount Wealth Management's SUPN Position: Q1 2019 in Review

Catamount Wealth Management held its Supernus Pharmaceuticals (SUPN) position steady in Q1 2019 at 150 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #159.

Catamount Wealth Management first reported a position in SUPN in Q4 2017 and has held it in 6 quarters since. The position peaked at $8K in Q3 2018. 289 funds tracked by Wall St. Rank hold SUPN as of Q1 2019.

  • Catamount Wealth Management held 150 shares of Supernus Pharmaceuticals worth $5K as of Q1 2019.
  • Catamount Wealth Management left its Supernus Pharmaceuticals share count unchanged in Q1 2019.
  • Supernus Pharmaceuticals made up ﹤0.01% of Catamount Wealth Management's portfolio in Q1 2019, its #159 holding.
  • Catamount Wealth Management first reported a position in Supernus Pharmaceuticals in Q4 2017 and has held it in 6 quarters since.
  • Catamount Wealth Management's Supernus Pharmaceuticals position peaked at $8K in Q3 2018.
  • 289 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2019.

Based on Catamount Wealth Management's 13F filing for Q1 2019, filed 3 May 2019.